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Abstract: High-throughput screening (HTS) of ~50,000 chemical compounds against phosphorylated and unphosphory-
lated c-Met, a tyrosine kinase receptor for hepatocyte growth factor (HGF), was carried out in order to compare hit rates, 
hit potencies and also to explore scaffolds that might serve as potential leads targeting only the unphosphorylated form of 
the enzyme. The hit rate and potency for the confirmed hit molecules were higher for the unphosphoryalted form of c-
Met. While the target of small molecule inhibitor discovery efforts has traditionally been the phosphorylated form, there 
are now examples of small molecules that target unphosphorylated kinases. Screening for inhibitors of unphosphorylated 
kinases may represent a complementary approach for prioritizing chemical scaffolds for hit-to-lead follow ups.  
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INTRODUCTION 
  There are approximately 500 protein kinases encoded in 
the human genome. As protein kinases often play critical 
roles in signaling cascades, they are important regulators of 
virtually all physiological process. Given that kinase activity 
is often disregulated in disease processes, protein kinases 
represent an attractive class of drug targets for small mole-
cule intervention and potentially make up over one quarter of 
all pharmaceutical drug targets being pursued [1, 2]. As 
such, there is much interest in discovering novel small mole-
cule kinase inhibitor scaffolds for pharmaceutical develop-
ment and drug discovery. Protein kinase domains share a 
common fold which can be divided into an N-terminal 
mostly -strand lobe and a C-terminal mostly -helical lobe. 
The so-called activation loop is centrally located between the 
two kinase lobes. The standard model for kinase activation 
requires phosphorylation on the activation loop. In general, 
phosphorylation results in large inter-lobe conformational 
changes and a significant increase in the catalytic activity of 
the kinase domain [3]. However, several examples of protein 
kinases that either do not show activation upon phosphoryla-
tion [4] or show significant activity in the unphosphorylated 
form [5] are known. While traditional small molecule drug 
discovery has focused on the phosphorylated “active” form 
of protein kinases, recently the unphosphorylated “inactive” 
form is being considered as an attractive form to target for a 
variety of reasons [6]. For example it is thought that there is 
considerably more conformational states in unphosphory-
lated kinases which can then be exploited to achieve selectiv-
ity. In particular, it maybe possible to find inhibitors that 
preferentially bind to conformations only populated by the 
unphosphorylated form. 
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  c-Met is a tyrosine kinase receptor for hepatocyte growth 
factor (HGF) that is often deregulated in human cancers 
making it an attractive drug target. It is a disulfide-linked 
heterodimeric receptor that results from proteolytic process-
ing of a single chain precursor. Binding of HGF to c-Met 
results in autophosphorylation of the activation loop at a pair 
of tandem tyrosine residues (residues 1234 and 1235) and 
receptor multimerization. This causes increased tyrosine 
kinase activity, phosphorylation at additional sites in the c-
Met cytoplasmic domain of c-Met, recruitment of adaptor 
proteins and finally downstream activation of various af-
fecters including PI-3-Kinase, PLC-, STATs, ERK 1 and 2, 
and FAK. Activation of c-Met and its downstream pathways 
result in increased cell growth and motility and decreased 
apoptosis, which has casually linked this pathway to a wide 
variety of tumor types [7]. As such, c-Met is an attractive 
candidate for development of anti-tumor therapies
 [8]. 
  Gleevec is a currently approved drug for the treatment of 
chronic myelogenous leukemia (CML) and is a hallmark 
targeted therapeutic in oncology [9]. It has been shown to 
target the unphosphorylated form of Bcr-Abl
 [4, 10]. Given 
the success of Gleevec and the general observation that 
kinases occupy different conformational states depending 
upon phosphorylation state, we hypothesized that high 
throughput screening of the two kinase forms might have 
different hit rates and identify different lead molecules. We 
screened a chemical library against phosphorylated and un-
phosphorylated c-Met to test this hypothesis. The screen 
yielded a higher hit rate for unphosphorylated c-Met. Several 
of the hits identified against the unphosphorylated form of c-
Met did not measurably inhibit the phosphorylated form. 
These compounds are potentially good starting points for 
medicinal chemistry efforts. While future medicinal chemis-
try will be needed to establish the chemical tractability of 
these phosphorylation state dependent hits, we discuss other 
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phosphorylated form of c-Met in cancer cell lines thus indi-
cating that the approach is feasible in biologically relevant 
assays. Future screening and chemistry efforts will be 
needed to see if this approach is more generally applicable to 
other tyrosine kinases. 
MATERIALS AND METHODS 
c-Met Cloning, Expression and Purification 
  Production of phosphorylated and unphosphorylated c-
Met: Residue 956 through 1391 (the catalytic domain) of 
human c-Met was amplified with an N-terminal 6X-HIS tag 
using the polymerase chain reaction and human liver cDNA. 
The resulting fragment was cloned into pENTR (Invitrogen, 
CA), sequence confirmed and transferred to pDEST8 using 
the Invitrogen Gateway System. Baculovirus was generated 
with the cMET/pDEST8 clone following the general proce-
dures of the Bac-to-Bac Baculovirus Expression Systems 
(Invitrogen, CA). E.coli DH10Bac cells were transformed 
with the cMET/pDEST8 clone and Bacmid DNA was pre-
pared for transfection into Sf21 insect-cells. Conditioned 
medium containing baculovirus particles was collected from 
the transfected cells and used for additional infections of 
Sf21 cells for amplification of the virus. Production of un-
phosphorylated c-Met was achieved by expressing full 
length protein tyrosine phosphatase 1B (PTB1B) using an 
equivalent procedure.  
  The phosphorylated form of the human c-Met catalytic 
domain was optimized for expression in Sf21 cells grown in 
Expression Systems ESF 921 serum-free medium. Cells 
were infected with baculovirus at a multiplicity of infection 
(MOI) of 5 and harvested 48 hours post-infection. Unphos-
phorylated human c-Met (catalytic domain) was produced by 
baculovirus coinfected with human full-length PTP-1B tyro-
sine phosphatase at a MOI ratio of 1:1 in Sf21 cells for 48 
hours. The degree or lack of phosphorylation was examined 
by western analysis using both anti-phospho c-Met 
(pY1234/pY1235, the activation loop phosphorylation sites) 
and anti-phosphotyrosine antibodies on both the cell lysate 
and purified protein. The cells were suspended in cold lysis 
buffer (100 mM potassium phosphate, pH 7.5/250 mM 
NaCl/5% glycerol/5 mM BME/1% Triton) and lysed by 
dounce homogenization. The His-tagged c-Met protein was 
bound to Ni-NTA sepharose, washed with buffer (100 mM 
potassium phosphate, pH 7.5/250 mM NaCl/5% glycerol/5 
mM BME) containing 10 mM and 40 mM imidazole with 
100- and 20-column volumes, respectively. His-tagged c-
Met was eluted with 10-column volumes of 300 mM imida-
zole in the same buffer. Eluted protein was dialyzed against 
the same buffer, concentrated and reloaded on a Talon col-
umn. The column was washed with 60- and 10-column vol-
umes of 10 mM and 25 mM imidazole, respectively. c-Met 
was eluted with 10-column volumes of 150 mM imidazole. 
Western Analysis 
  For the western blotting analysis, unphosphorylated and 
phosphorylated c-Met samples were resolved on SDS-12% 
PAGE gel and transferred to PVDF membrane (Invitrogen, 
CA). Phosphorylation was detected using anti-
phosphotyrosine or anti-phospho c-Met (pY1234/pY 1235) 
(Cell Signal, MA) antibodies using standard protocols.  
c-Met Kinase Assay  
  The assay buffer contained 50 mM Tris-HCl, 10 mM 
MgCl2, 100 mM NaCl, 0.1 mg/ml BSA, 5mM DTT, pH 7.8. 
For HTS 0.8 μL of 5 mM of the test compounds dissolved in 
DMSO were dotted on 384-well plates. DMSO titration sug-
gested that the maximum tolerated concentration of the sol-
vent is 4%. To measure IC50s the compound plate was pre-
pared by 3-fold and 11-point serial dilutions. 0.8 μL of the 
compound in DMSO was transferred from the compound 
plate to the assay plate. The final concentration of DMSO 
was 2%. Solutions of 8 nM unphosphorylated c-Met or 0.5 
nM phosphorylated c-Met were prepared in assay buffer. A 1 
mM stock solution of peptide substrate Biotin-
EQEDEPEGDYFEWLE-amide (Quality Controlled Bio-
chemicals, MA) dissolved in DMSO was diluted to 1 μM in 
assay buffer containing 400 μM ATP (unphosphorylated c-
Met) or 160 uM ATP (phosphorylated c-Met). A 20 μL vol-
ume of enzyme solution (or assay buffer for the enzyme 
blank) was added to the appropriate wells in each plate and 
then 20 μL/well of substrate solution to initiate the reaction. 
The plate was protected from light and incubated at 25 °C 
for 90 min. The reaction was stopped by adding 20 μL of a 
solution containing 45 mM EDTA, 50 mM Tris-HCl, 50 mM 
NaCl, 0.4 mg/ml BSA, 200 nM SA-APC and 3 nM EU-
Py20. The plate was incubated for 15-30 min at room tem-
perature and HTRF (homogenous time resolved fluores-
cence) was measured on a Perkin Elmer Fusion -FP in-
strument. The HTRF program settings used were as follows: 
Primary excitation filter 330/30, Primary window: 200 uSec, 
Primary delay: 50 uSec, Number of flashes: 15, Well read 
time: 2000 Sec, Secondary excitation filter: 330/30, Secon-
dary window: 400 Sec, Secondary delay: 400 Sec, Pri-
mary, Secondary delay: 400 Sec, Primary emission filter: 
EM 665/10, Secondary emission filter EM 620/10. Percent-
age of inhibition was calculated for each concentration and 
IC50 value was generated from curve fitting with GraphPad 
Prism 3 software. The Km values for ATP were measured in 
the presence of 1 μM substrate peptide. 
RESULTS AND DISCUSSION 
Production and Characterization of c-Met forms 
  We produced the catalytic domain of c-Met using the 
baculovirus expression system. Because c-Met has been 
shown to be a substrate for protein tyrosine phosphatase 1B 
(PTP1B), unphosphorylated and phosphorylated c-Met was 
generated in the presence and absence of coexpressed 
PTP1B, respectively
  [5]. Phosphorylation of c-Met was 
monitored by western analysis using both anti-phospho c-
Met (pY1234/pY1235, the activation loop phosphorylation 
sites) and anti-phosphotyrosine antibodies. Expression of c-
Met in the absence of PTP1B produced a kinase that had 
significant phosphorylation of the activation loop while c-
Met expressed in the presence of PTP1B produced no de-
tectable phosphorylation either in the activation loop or else-
where in the kinase domain (Fig. 1). Given the 100-fold 
higher protein load for the unphosphorylated form and lack 
of detectable phosporylation in that form by western analy-
sis, we conservatively estimate that the level of phosporyla-
tion must be less than 0.1%. Similar results have been re-
ported elsewhere using Escherichia coli as an expression 
host [5].  Phosphorylation State-Dependent HTS of c-Met  Current Chemical Genomics, 2010, Volume 4    29 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Western blot analysis of total phosphorylation of Met. 
Samples of 5 g and 50 ng of unphosphorylated (right band) and 
phosphorylated (left band) c-Met, respectively were resolved by 
SDS-PAGE under reducing conditions (upper panel). Phosphoryla-
tion content was determined using pan anti-phosphotyrosine anti-
bodies (middle panel). Phosphorylation of Y1234 and Y1235 was 
detected by anti-phospho c-Met (pY1234/pY 1235 (lower panel).  
 
  Steady state kinetic analysis was undertaken for each 
form of the enzyme. The phosphorylated and unphosphory-
lated forms of c-Met show Km values for ATP of 60 ± 12 and 
200 ± 38 μM, respectively. Relative Kcat values were deter-
mined to be 1.0 and 0.065 for phosphorylated and unphos-
phorylated forms, respectively (Table 1). While traditionally 
unphosphophoryalted forms of kinases were assumed to be 
enzymatically inactive several other unphosphorylated 
kinases have also be reported to be catalytically active
 [10- 
12]. The activity of unphosphorlayted kinases may represent 
a basal signaling level in cellular environments. The two 
forms of c-Met are clearly kinetically distinguishable as re-
flected by effects on both Kcat and Km in steady state kinetic 
analysis. 
Table  1.  Kinetic Parameters for Phosphorylated and Un-
phosphorylated c-Met 
Enzyme Form  Km,ATP (M) Relative  Kcat (min
-1) 
Phospho c-Met  60 ± 12  1 
Un Phospho c-Met  200 ± 38  0.065 
The Km for ATP was measured at 1 M peptide substrate. 
 
  While it is theoretically possible that unphosphorylated c-
Met undergoes autophosphorylation under the assay condi-
tions, this seems unlikely for several reasons. 1) No phos-
phorylation was detected by western analysis after incubat-
ing this form of the enzyme under assay conditions (data not 
shown) 2) product formation was linear with time (see Fig. 
2). Since the phosphorylated enzyme has higher catalytic 
activity, c-Met phosphorylation during the kinase assay 
would have resulted in upward curvature for product forma-
tion. Timofeevski et al. noted increase in Kcat over time un-
der conditions where autophosphorylation can occur
 [13]. No 
such change is observed under our reaction conditions. 3) As 
will be shown below, the two forms of the enzyme have re-
producible and different IC50 values for a series of inhibitors 
(Figs. 3A & D). 4) The low concentrations of the kinase in 
the assay make trans-autophosphorylation unlikely. Ti-
mofeevski et al. noted strong c-Met concentration depend-
ence for autophosphorylation [13] and performed autophos-
phorylation reactions at 10 uM enzyme (in the presence of 4 
mM ATP at 4 °C which can overall lead to ~2-fold decrease 
in the catalytic activity compared to 200 M ATP at 25 ºC). 
Their c-Met concentrations are 2500-fold higher than in the 
enzyme assays conducted here. 
 
 
 
 
 
 
 
 
 
Fig. (2). Time course of the phsophorylation of the peptide sub-
strate by unphosphorylated Met. 4 nM of unphosphorylated c-Met 
was incubated with 1 μM of peptide substrate Biotin-
EQEDEPEGDYFEWLE-amide and 200 μM ATP. The reaction 
was carried out at 25 ºC in 50 mM Tris-HCl, 10 mM MgCl2 ,100 
mM NaCl, 0.1 mg/ml BSA, 5mM DTT, pH 7.8. Points are dupli-
cates and the data were fit to a line. 
 
Screening of Small Molecule Libraries  
  42,000 compounds from the ChemBridge collection were 
screened against phosphorylated and unphosphorylated c-
Met. ChemBridge is a collection of 450,000 verified, drug-
like, diverse, small molecule compounds. The assay per-
formed well over the course of the screen; control wells for 
each plate averaged a signal/background ratio of 8.6 with Z´ 
(Z´ = 1- ([3 X STD negative control] + [3 X STD positive con-
trol])/(mean  positive control – mean negative control) of 0.74 for the 
unphosphorylated and 14.5 and 0.81 for the phosphorylated 
form, respectively. The concentration-response curves for 
the positive control, SU11274, included on every screening 
plate, were consistent, with median minimum significant 
ratio (MSR) value of 1.3 for phosphorylated and 1.2 for un-
phophorylated
 [14]. The Z´ and MSR values for both assays 
indicate that the screening efforts would be expected to be 
robust and reliable. 
  The compounds were tested at 100 M. All compounds 
that exhibited greater than 30% inhibition against either form 
of the enzyme were then retested against both forms by de-
termining their IC50 values. The hits that had been shown to 
test positive against non-kinase targets from other HTS cam-
paigns were eliminated as false positives (~11% of the total 
hits). Using a 30 M cutoff for potency when defining a hit, 
the hit rate for phosphorylated c-Met was 0.09 % (38 total 
hits) while the hit rate for unphosphorylated c-Met is 0.13% 
(56 total hits). The hit rate for unphosphorylated c-Met was ~ 
44% higher than for phosphorylated c-Met. While this ratio 
of hit rates might change if larger numbers of compounds 
were screened, it is clear that for the limited set tested there 
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is a higher number of potential lead molecules generated 
when screening with the unphosphorylated form of the en-
zyme. Inspection of the relative potencies for compounds 
indicates that the majority of compounds are roughly equally 
potent on both forms of c-Met with ratios close to 1.0 (Fig. 
3C). There are however, compounds that exhibit at least a 5-
fold more potent IC50 value for unphosphorylated c-Met rela-
tive to phosphorylated c-Met (Table 2). In fact of the 56 hits 
for unphosphorylated c-Met, six have greater than 5-fold 
specificity. These hits (ratios >5), four of which with purine 
moities and two of which with a novel benzyloxybenzalde-
hyde oxime core structure, represent potential lead molecules 
that would not have been identified by screening only the 
phosphorylated form of c-Met. On the other hand, no com-
pound shows significantly greater potency on the phosphory-
lated form (ratio significantly <1.0) which accounts for the 
increased hit rate for the unphosphorylated form. From a 
structural perspective, the specific molecules must be bind-
ing to a conformation that only the unphosphorylated form 
can easily adopt. The nonspecific molecules, on the other 
hand, must bind to a conformation that is present in both 
forms of the enzyme. The scenario is quite plausible given 
the known large conformation changes that kinases undergo 
and that the conformation preferences are in large part de-
termined by phosphorylation state
 [15].  
  We also examined two published kinase inhibitors that 
inhibit c-Met. Staurosporine is a well known ATP-
competitive nonspecific kinase inhibitor. SU11274 is a 
commercially available potent c-Met inhibitor. SU11274 is a 
well studied specific ATP-competitive inhibitor and has been 
shown to be active against numerous cancer cell lines
 [16-
18]. Table 2 and Figs. (3A and 3B) show the IC50 values for 
these two inhibitors. Staurosporine has essentially the same 
IC50 value for both forms of the enzyme while SU11274 is 5 
nM on the unphosphorylated form and 275 nM on the phos-
phorylated form, a 55-fold difference in potency. Further-
more, the IC50 for SU11274 is 30 nM in SNU5 proliferation 
assays. SNU5 is a gastric cancer cell line in which c-Met is 
amplified. Given that the compound is more potent on cells 
than on the phosphorylated form of the enzyme, it is likely 
that the cellular activity is being driven by inhibition of the 
unphosphorylated enzyme. The discrepancy is even larger 
when one accounts for the high cellular ATP concentrations 
of approximately 1 mM (predicted IC50 values for SU11274 
are 30 nM and 3331 nM for the phosphorylated and unphos-
phorylated forms, respectively). We have noted the same 
trend with a large number of compounds in our internal c-
Met program.  
  The observations made during our screening endeavor 
and examination of known c-Met inhibitors convinced us to 
examine our internal kinase library for additional inhibitors 
of the unphosphorylated form. The internal library is a com-
pound collection that resulted from medicinal chemistry ef-
forts on several unrelated kinase targets. All chemical series 
were shown to be ATP competitive against their respective 
kinase target.  
  Using a 30 M cutoff for potency when defining a hit, 
the hit rate for phosphorylated c-Met was 1.0 % (73 total 
hits) while the hit rate for unphosphorylated c-Met was 0.89 
% (62 total hits). The hit rate for unphosphorylated c-Met 
was similar to the phosphorylated c-Met. While screening a 
random library led us discover potential lead molecules that 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Comparison of dose-dependent inhibition of phosphorylated and unphosphorylated c-Met by small molecule inhibitors. 4 nM of the 
unphosphorylated was incubated with 1 μM of peptide substrate, 200 μM ATP and small molecule inhibitors (filled triangles) for 90 minutes 
at 25 ºC. 0.25 nM of the phosphorylated c-Met was mixed with1 μM of peptide substrate 80 μM ATP and small molecule inhibitors (open 
squares) for 90 minutes at 25 ºC. Hit 7 is from Table 2 and Hit 3 is from Table 3. Points are duplicates normalized to 100% for the uninhibi-
ted kinase. Data were fit to a hyperbola on logarithmic scale. 
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inhibit unphosphorylated c-Met, screening our internal 
kinase inhibitors (Table 3) resulted in identifying seven 
compounds that were 5-fold or more potent against the 
phosphorylated form (ratio significantly <1.0). For example, 
while Hit 1 and 2 inhibit the phosphorylated form with IC50s 
of 11 and 4.2 M respectively, they do not inhibit the un-
phosphorylated form. There are also compounds which do 
not inhibit the phosphorylated form but are relatively potent 
against unphosphorylated c-Met (Hit 3 and 4). In fact six 
compounds from the 62 hits were identified to be 5-fold or 
more selective for unphosphorylated form. The screening of 
our internal kinase collection has shown that it is possible to 
obtain compounds that are more potent on the phosphory-
lated c-Met. Most of these compounds had a common core 
of benzoimidazo (or thiozolo) isoquiolinon, a known kinse 
scaffold. These compounds presumably bind a conformation 
(or induce a conformation) that is preferred by the phos-
phorylated form and/or disfavored by the unphosphorylated 
form. 
CONCLUSION 
  We have shown that screening the unphosphorylated and 
phosphorylated form of c-Met yields different hit molecules. 
Screening of random and kinase libraries, it was possible to 
find molecules that are equipotent on both forms, more po-
tent on the unphosphorylated form and more potent on the 
phosphorylated form. The specific inhibitors likely exploit 
different conformational preferences between the two forms 
Table 2.  IC50 Values for Screening Hits (General Library) 
Compound unP-IC50 (M)
1 P-IC50 value (M)
2 Ratio
3 
Hit  1 10.0  >100 >10 
Hit 2  14.0  >60  >4 
Hit 3  27  >100  >4 
Hit 4  19.0  >60  >3 
Hit 5  11.0  59.0  5.4 
Hit 6  15.0  >100  >7 
Hit 7  2.5  2.5  1 
Staurosporine 0.028  0.057  2.0 
SU11274 0.005  0.28  56.0 
1IC50 value for the unphosphorylated form of c-Met. 
2IC50 value for the phosphorylated form of c-Met. 
3Ratio = IC50 value for phosphorylated form / IC50 value for the unphosphorylated form. 
 
Table 3.  IC50 Values for Screening Hits (Internal Kinase Inhibitors Collection) 
Compound unP-IC50 (M)
1 P-IC50 value (M)
2 Ratio
3 
Hit 1  >60  11  <0.2 
Hit 2  >60  4.2  <0.1 
Hit 3  3.5  >60  >17 
Hit 4  3.9  >60  >15.4 
Hit 5  4.5  1.0  0.2 
Hit 6  0.1  0.5  5 
Hit 7  >100  10  <0.1 
Hit 8  >100  4  <0.04 
Hit 9  106  8  0.08 
Hit 10  1.4  26  19 
Hit 11  4.5  220  49 
Hit 12  65  3.9  0.06 
Hit 13  1  5.7  5.7 
1IC50 value for the unphosphorylated form of c-Met. 
2IC50 value for the phosphorylated form of c-Met. 
3Ratio = IC50 value for phosphorylated form / IC50 value for the unphosphorylated form 32    Current Chemical Genomics, 2010, Volume 4  Behshad et al. 
of c-Met. As is well known, kinases undergo large confor-
mational changes upon phosphorylation [15]. Structural 
studies would be needed to examine this further in the case 
of the inhibitors explored here. However, there is precedent 
for this approach. Gleevec is an Abl kinase inhibitor that is 
approved for the treatment of chronic myelogenous leukemia 
(CML)
 [19]. It has been shown that Gleevec is significantly 
more potent on the unphosphorylated from of Abl kinase and 
that the inhibitor binds to an inactive conformation that only 
unphosphorylated Abl can easily adopt [4, 10]. Interestingly, 
Abl has also been shown to have activity in the unphos-
phorylated form [4, 10]. Gleevec also falls into “type II” 
class of inhibitors [6]. This class of inhibitors contains a hy-
drogen bond donor-acceptor pair (amide or urea) and a hy-
drophobic tail that interact with the “allosteric site”. Most of 
them also contain a “head“ group that extends into the ade-
nine region. They have been shown to bind to the unphos-
phorylated form and induce or stabilize an inactive confor-
mation. While Gleevec falls into this category there are ex-
amples of type I inhibitors that bind to the unphosphorylated 
form more tightly. SU11274 is one example which was dis-
cussed earlier and AM7 is another. AM7, (5-(3-fluoro-4-((6-
(methyloxy)-7-((3-(4 morpholinyl)prpyl)oxy)-4-quinolinyl) 
oxy)phenyl)-3-methyl-2-(phenylmethyl)-4(3H)-pyrimidin-
one) developed by Amgen, was shown to be more than 3-
fold more potent on unphosphorylated Met (IC50 of 5 vs. 17 
nM)
18
. Interestingly the binding mode of AM7 seems to be 
different from SU11274 (which is also different from how a 
type I inhibitor would bind). They both bind to the kinase 
linker but AM7 extends into the C-helix hydrophobic region 
which is 8 Å away from the DFG pocket. While SU11274 
and AM7 bind to the unphosphorylated form more tightly, 
Pan and co-workers recently identified MK2461 that binds to 
the phosphorylated enzyme 6-fold tighter [20]. These exam-
ples illustrate that there exists many conformations available 
to both phosphorylated and unphosphorylated kinases.  
  The results presented above show that different hit mole-
cules are obtained by screening the phosphorylated and un-
phosphorylated forms of c-Met kinase. Future research will 
be required to determine the tractability of these particular 
hits. While it is unlikely that all of these hits can be suffi-
ciently pursued, there is clearly a number of potential new 
scaffolds when all screening hits are evaluated. It is intrigu-
ing to speculate that this approach could be employed to tar-
get other kinases; however, this methodology is perhaps 
more productive for kinases that have some characteristics 
similar to c-Met. As noted above, c-Met has significant cata-
lytic activity in the unphosphorylated form. This may indi-
cate that structural characteristics that allow for inhibition in 
the unphosphorylated form may not be present in kinases 
without activity prior to phosphorylation. It is notable that 
Gleevec, a marketed drug for AML, is the prototypical in-
hibitor of an unphosphorylated kinase target and that its tar-
get, Abl, has catalytic activity that is little changed upon 
phosphorylation of its activation loop [10]. Additionally, it 
may be easier to translate activity against an unphosphory-
lated form from an enzyme assay to a cellular context by 
targeting kinases that autophosphorylate, typically tyrosine 
kinases. In this context, during the continual autophosphory-
lation and dephosphorylation by protein phosphatases, bind-
ing to the unphosphorylated form of a kinase may shift the 
“equilibrium” to the unphosphorylated, generally less active, 
form. Should the activity present in unphosphorylated 
kinases translate to a basal level of signaling in cellular con-
texts, binding of the unphosphorylated form may also reap 
additional pharmacological benefit as inhibitors that don’t 
bind this form would not impact this basal level of signaling. 
This scenario is unlikely to apply for kinases that are part of 
kinase cascades and are phosphorylated by upstream, often 
unrelated, kinases. These are more typically serine/threonine 
kinases. Future studies will be required to address these is-
sues. It should also be pointed out that it may be possible to 
initiate chemistry efforts on compounds that are specific for 
an unphosphorylated form but build in potency for the phos-
phorylated form during the medicinal chemistry optimization 
process. Screening the unphosphorylated form of a kinase 
can provide a richer ensemble of screening hits for this type 
of approach. 
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